This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Garlic in Patients With Febrile Neutropenia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2013 by Moshe Gatt, Hadassah Medical Organization.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Moshe Gatt, Hadassah Medical Organization Identifier:
First received: October 31, 2005
Last updated: July 4, 2013
Last verified: July 2013
To determine the clinical effects of garlic in preventing and treatment of patients with chemotherapy related febrile neutropenia.These patients have a very high incidence of infections which are not routinely covered by the standard empiric therapy. Adding a non- toxic and possibly effective therapy may reduce the risk for infections, synergize the empiric antibiotic treatment and may lessen the need for broader spectrum and more severe side effects.

Condition Intervention Phase
Chemotherapy Neutropenia Dietary Supplement: Solgar Israel Other: Placebo capsules Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Controlled Study to Determine The Clinical Efficacy Of Garlic Compounds In Patients With Chemotherapy Related Febrile Neutropenia

Resource links provided by NLM:

Further study details as provided by Moshe Gatt, Hadassah Medical Organization:

Primary Outcome Measures:
  • Time to fever and beginning of empiric antibiotic treatment. [ Time Frame: 0-45 days post chemotherapy ]

Secondary Outcome Measures:
  • Documented and culture positive infections. [ Time Frame: as above ]
  • Kind of infectious organisms and sensitivity to medicines. [ Time Frame: as above ]
  • Length of infection [ Time Frame: as above ]
  • Use of growth factors. [ Time Frame: as above ]

Estimated Enrollment: 120
Study Start Date: June 2006
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Garlic extract
Garlic extract capsules
Dietary Supplement: Solgar Israel
Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
Placebo Comparator: Placebo
Placebo capsules
Other: Placebo capsules
placebo capsules

Detailed Description:
Patients eligible are randomized to receive placebo or garlic capsules after chemotherapy course and until leukocyte recovery.

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

FN patients expected to have at least 5 days or more of neutropenia will be eligible for treatment with garlic compounds AST/ALT ≤ 3 times the upper limit of institutional laboratory normal.

Total bilirubin ≤ 2 times the upper limit of institutional laboratory normal.

BUN and creatinine should be ≤ 3 times the upper limit of institutional laboratory normal.

Newly diagnosed as well as previously treated patients will be eligible.

Exclusion Criteria:

History of clinically significant liver or kidney disease.

Patients on anti-coagulation therapy with Coumadin will be excluded because of the potential garlic interference with metabolism.

Patients receiving concomitant chemotherapeutic treatment

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00247039

Contact: moshe e gatt, dr 972-50-5172333

Hadassah Medical Organization Recruiting
Jerusalem, Israel
Contact: arik Tzukert, DMD    00 972 2 6777572   
Principal Investigator: moshe e gatt, dr         
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: moshe e gatt, dr Hadassah Medical Organization
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Moshe Gatt, Dr. Moshe Gatt, Hadassah Medical Organization Identifier: NCT00247039     History of Changes
Other Study ID Numbers: 384 gar 1- HMO-CTIL
GAR1 ( Other Grant/Funding Number: Dunsky grant for cancer research )
Study First Received: October 31, 2005
Last Updated: July 4, 2013

Keywords provided by Moshe Gatt, Hadassah Medical Organization:

Additional relevant MeSH terms:
Febrile Neutropenia
Leukocyte Disorders
Hematologic Diseases processed this record on August 18, 2017